Provides WAT Med’s official announcements, including new product launches, awards, certifications, and other key updates.
VANCOUVER, BC, August 17th, 2026 /PRNewswire/ Participant recruitment information for a clinical study being conducted at The Ohio State University has been publicly posted on ClinicalTrials.gov. The study, titled “Evaluating the Effect
VANCOUVER, BC, June 17, 2026 /PRNewswire/ WAT Medical proudly announces that it has successfully obtained a Manufacturing Site Registration Certificate issued by the UAE Ministry of Health & Prevention (MOHAP) in June 2026, marking
VANCOUVER, BC, February 9th, 2026 /PRNewswire/ — WAT Medical is proud to announce the publication of a landmark randomized clinical trial in JAMA Surgery, one of the world’s most reputable and
Introduction At WAT Medical, sustainability is integrated into the full lifecycle of our non-drug neuromodulation solutions, including EmeTerm for nausea relief and HeadaTerm for migraine management. We believe that true
VANCOUVER, BC, November 3rd, 2025 /PRNewswire/ — WAT Medical Enterprise Ltd. proudly announced the publication of a groundbreaking clinical trial in The Journal of Bone & Joint Surgery (JBJS) which demonstrates the significant benefits
VANCOUVER, BC, September 15, 2025 /PRNewswire/ – WAT Medical Enterprise Ltd. is proud to announce that its innovative anti-nausea wristband, EmeTerm, has made significant progress in alleviating nausea and vomiting among
VANCOUVER, BC, June 16, 2025 /PRNewswire/ — WAT Medical Enterprise Ltd. is pleased to announce that its migraine relief device, HeadaTerm 2, is now featured on the American Migraine Foundation’s (AMF)
VANCOUVER, BC, Jan.13, 2025 /PRNewswire/ —WAT Medical Enterprise collaborated with Concordia University and Mitacs Canada to conduct a study using ObeEnd, the neuromodulation device designed for weight and health management. The study revealed
VANCOUVER, BC, Dec. 9, 2024 /PRNewswire/ — WAT Medical Enterprise proudly sponsored the 2024 Scottsdale Headache Symposium, organized by the American Headache Society from November 14-17 in Scottsdale, AZ. This annual event brought together a multidisciplinary
VANCOUVER, BC, Oct. 16, 2024 /PRNewswire/ — WAT Medical Enterprise proudly announces a significant achievement: both EmeTerm Smart and HeadaTerm 2 have received Medical Device Licences (MDL) from Health Canada. EmeTerm Smart
VANCOUVER, BC, Aug. 8, 2024 /PRNewswire/ — EmeTerm® Smart uses patented hybrid technology to seamlessly integrate the functionality of a smartwatch with that of an anti-nausea wristband, ensuring a carefree and healthy
WAT Medical proudly introduced HeadaTerm 2, an innovative wearable anti-migraine device, at the American Headache Society’s 66th Annual Scientific Meeting, held in San Diego, California. The device has recently received
